Search the Newsreel

Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 1,536,736 shares of Karyopharm Therapeutics Inc. (KPTI) common stock, representing a 6.78% stake. This includes 15,414 shares issuable upon the exercise of warrants. The filing indicates shared …

Arbutus Biopharma Q2 Results: EPS Misses Estimate, Sales Beat

Arbutus Biopharma earnings matched, revenue topped estimates

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

Vor Biopharma (NASDAQ:VOR) experienced a 6.5% drop in stock price following an earnings announcement where the company reported a quarterly EPS of negative $0.80, missing the consensus estimate of negative $0.69. Despite the disappointing earnings and reduced trading volume, the company maintains a "Moderate …

GTBP Q1 2026 Earnings: Wider Loss Misses Estimates as Clinical Investment Continues - Earnings Stability Report

Form 8K Sutro Biopharma For: 12 August By Investing.com

The article reports that Sutro Biopharma filed a Form 8K on August 12. It provides no further details on the content of the filing but mentions the stock symbol STRO, which was down 1.62%. The rest of the content includes market data, news headlines, …

Sutro Biopharma Announces Q2 2026 Financial Results and Updates Corporate Presentation

Sutro Biopharma, Inc. has announced its financial results for the second quarter ended June 30, 2026, and released an updated corporate presentation. These disclosures were made via a current report filed with the SEC, which included a press release detailing the quarterly performance and …

Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact

Arbutus Biopharma Corporation reported its Q2 2026 financial results, showcasing a significant net income of $164,552 thousand for the six months ending June 30, 2026, primarily due to $179,373 thousand in license revenue from Genevant. This marks a substantial improvement from a net loss …

COSCIENS Biopharma Stock Builds Positive Momentum as Q2 Efficiency Gains Strengthen TSX:CSCI Outlook

Sutro Biopharma earnings missed by $0.13, revenue fell short of estimates

J.P. Morgan Sticks to Its Hold Rating for Conocophillips (COP)

UBS raises ConocoPhillips stock price target on strong project pipeline

UBS has increased its price target for ConocoPhillips (NYSE:COP) to $153 from $143, maintaining a Buy rating, citing the company's strong project pipeline and positive second-quarter update despite CEO transition concerns. The analyst firm noted the company's robust cash flow growth outlook and improved …

What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings

Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary

Arbutus Biopharma Corp reported its Q2 2026 results with revenue of $1.01M and a net loss of ($5.14M), a significant decrease from the prior year's $10.74M revenue and $2.52M net income. The diluted EPS was ($0.03) compared to $0.01 a year earlier. Key business …

Earnings Flash (ABUS) Arbutus Biopharma Posts Q2 Loss $0.03 a Share, vs. FactSet Est of $0.02 Loss

Arbutus: Q2 Earnings Snapshot

Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout

Sutro Biopharma (STRO) revenue drops as cash rises after $110M stock sale

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus …

Sutro Biopharma Reports $9.8 Million Revenue in Q2 2026

Sutro Biopharma GAAP EPS of -$2.33 misses by $0.14, revenue of $9.84M misses by $1.2M

* Sutro Biopharma press release [https://seekingalpha.com/pr/20616182-sutro-biopharma-reports-second-quarter-2026-financial-results-and-provides-early-update-on] (STRO [https://seekingalpha.com/symbol/STRO]): Q2 GAAP EPS of -$2.33 misses by $0.14. * Revenue of $9.84M (-84.6% Y/Y) misses by $1.2M. MORE ON SUTRO BIOPHARMA * Seeking Alpha’s Quant Rating on Sutro Biopharma [https://seekingalpha.com/symbol/STRO/ratings/quant-ratings] * Historical earnings data for Sutro …

ConocoPhillips (NYSE:COP) Stock Rating Upgraded by Freedom Capital

Freedom Capital has upgraded ConocoPhillips (NYSE:COP) stock from "hold" to "strong buy," contributing to a generally positive analyst outlook. The company recently reported strong quarterly results, with EPS of $3.24 and revenue of $19.52 billion, surpassing estimates, and institutional investors own 82.36% of the …

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

HC Wainwright has lowered its Q3 2026 EPS estimate for Immix Biopharma (NASDAQ:IMMX) to a loss of $0.17 per share, down from a previous forecast of $0.14 loss, while maintaining a "Buy" rating and a $25 price target. This revision follows Immix Biopharma reporting …

Earnings Flash (CSCI.TO) COSCIENS Biopharma Inc. Reports Q2 Revenue $3.1M

Will COSCIENS Biopharma Inc. (CSCI) Beat Estimates Again in Its Next Earnings Report?

Goldman Sachs Sticks to Its Buy Rating for Conocophillips (COP)

Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite Fades - Wave Equality

QNTM Q4 2025 Earnings: Net Loss of $0.71 Per Share, Shares Slide 1.97 - Analyst Earnings Estimate

ABVC BioPharma (ABVC) Financials 2026 - Income Statement and Balance Sheet

Arbutus Biopharma (ABUS) Earnings Date and Reports 2026

Sutro Biopharma (STRO) Earnings Date and Reports 2026 $STRO

The Top 5 Analyst Questions From ConocoPhillips’s Q2 Earnings Call

ConocoPhillips (COP) PT Raised to $153 at UBS

UBS analyst Josh Silverstein has increased the price target for ConocoPhillips (NYSE: COP) to $153.00 from $143.00. The firm is maintaining a Buy rating on the stock. This update is part of a premium article on StreetInsider.com.

Theravance Biopharma (TBPH) Stock Caught Between Fading Gains And Royalty Doubts

Theravance Biopharma (TBPH) reported a significant shift from profit to loss in Q2 2026, with revenue declining by 20.9% year-over-year. The company's earnings per share also moved into negative territory, raising doubts about its reliance on lumpy royalty income and past one-off gains. Both …

What's Going On With COSCIENS Biopharma Inc. Stock Tuesday?

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement

Stephen J. Hill, the Chief Operating Officer of Lyell Immunopharma, Inc., conducted an automatic share sale on August 10, 2026. This transaction was carried out to cover tax obligations stemming from the settlement of his vested restricted stock units. The sale was reported in …